GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » YoY EPS Growth

Oruka Therapeutics (FRA:HQ1) YoY EPS Growth : -67.42% (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Oruka Therapeutics's YoY EPS Growth for the quarter that ended in Mar. 2025 was -67.42%.

Oruka Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2025 was €-0.37.

Oruka Therapeutics YoY EPS Growth Historical Data

The historical data trend for Oruka Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics YoY EPS Growth Chart

Oruka Therapeutics Annual Data
Trend Dec24
YoY EPS Growth
-

Oruka Therapeutics Quarterly Data
Mar24 Jun24 Sep24 Dec24 Mar25
YoY EPS Growth - - - - -67.42

Oruka Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Oruka Therapeutics's YoY EPS Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EPS Growth (A: Dec. 2024 )
=(Earnings per Share (Diluted) (A: Dec. 2024 )-Earnings per Share (Diluted) (A: . 20 ))/ | Earnings per Share (Diluted) (A: . 20 ) |
=(0-)/ | |
=N/A %

Oruka Therapeutics's YoY EPS Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY EPS Growth (Q: Mar. 2025 )
=(Earnings per Share (Diluted) (Q: Mar. 2025 )-Earnings per Share (Diluted) (Q: Mar. 2024 )) / | Earnings per Share (Diluted) (Q: Mar. 2024 )) |
=(-0.37--0.221)/ | -0.221 |
=-67.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oruka Therapeutics YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » YoY EPS Growth
Comparable Companies
RAPP PGEN RGNX TRML ZBIO AURA FULC ATYR SVRA ITOS VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
ORKA:USA HQ1:Germany
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Website
https://www.orukatx.com
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Oruka Therapeutics Headlines

No Headlines